Afinitor

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

everolimus

Available from:

Novartis Europharm Limited

ATC code:

L01XE10

INN (International Name):

everolimus

Therapeutic group:

Aġenti antineoplastiċi

Therapeutic area:

Carcinoma, Renal Cell; Breast Neoplasms; Pancreatic Neoplasms

Therapeutic indications:

L-ormon tat-riċettur pożittiva tas-sider avvanzat cancerAfinitor huwa indikat għall-kura ta 'l-ormon tat-riċettur-pożittivi, HER2/neu negattivi għall-kanċer tas-sider avvanzat, f'kombinazzjoni ma exemestane, fil-nisa wara l-menopawsa mingħajr sintomatika vixxerali-marda wara l-rikorrenza jew l-progressjoni wara mediċini mhux sterojdi ta' inibitur aromatase. Newroendokrinika tumuri tal-frixa originAfinitor huwa indikat għall-kura ta li ma jistgħax jitneħħa kirurġikament, jew li mmetastatizza, sew jew moderatament differenzjati newroendokrinika tumuri tal-frixa-oriġini fl-adulti bil-marda progressiva. Newroendokrinika tumuri tal-gastro-intestinali jew tal-pulmun originAfinitor huwa indikat għall-kura ta li ma jistgħax jitneħħa kirurġikament, jew li mmetastatizza, differenzjat tajjeb (Grad 1 jew ta ' Grad 2) mhux funzjonali newroendokrinika tumuri tal-gastro-intestinali jew tal-pulmun-oriġini fl-adulti bil-marda progressiva. Renali taċ-ċelluli carcinomaAfinitor huwa indikat għall-kura ta ' pazjenti b'indeboliment avanzat tal-karċinoma taċ-ċellola, li l-marda tagħhom mexa fuq jew wara l-kura bil-VEGF-terapija fil-mira.

Product summary:

Revision: 30

Authorization status:

Awtorizzat

Authorization date:

2009-08-02

Patient Information leaflet

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Afinitor 2.5 mg pilloli
Afinitor 5 mg pilloli
Afinitor 10 mg pilloli
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Afinitor 2.5 mg pilloli
Kull pillola fiha 2.5 mg everolimus.
_Eċċipjent b’effett magħruf_
Kull pillola fiha 74 mg lactose.
Afinitor 5 mg pilloli
Kull pillola fiha 5 mg everolimus.
_Eċċipjent b’effett magħruf_
Kull pillola fiha 149 mg lactose.
Afinitor 10 mg pilloli
Kull pillola fiha 10 mg everolimus
_Eċċipjent b’effett magħruf_
Kull pillola fiha 297 mg lactose.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola.
Afinitor 2.5 mg pilloli
Pilloli minn bojod sa kemxejn sofor, tawwalin b’qies ta' madwar 10.1
mm fit-tul u 4.1 mm fil-wisa',
b’ġenb tasturat u bl-ebda sinjal dritt, imnaqqxin b’“LCL” fuq
naħa waħda u “NVR” fuq in-naħa
l-oħra.
Afinitor 5 mg pilloli
Pilloli minn bojod sa kemxejn sofor, tawwalin b’qies ta' madwar 12.1
mm fit-tul u 4.9 mm fil-wisa',
b’ġenb tasturat u bl-ebda sinjal dritt, imnaqqxin b’“5” fuq
naħa waħda u “NVR” fuq in-naħa l-oħra.
Afinitor 10 mg pilloli
Pilloli minn bojod sa kemxejn sofor, tawwalin b’qies ta' madwar 15.1
mm fit-tul u 6.0 mm fil-wisa',
b’ġenb tasturat u bl-ebda sinjal dritt, imnaqqxin b’“UHE” fuq
naħa waħda u “NVR” fuq in-naħa
l-oħra.
3
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Kanċer tas-sider avvanzat bl-ormonu tar-riċettur pożittiv
Afinitor hu indikat għall-kura ta’ kanċer tas-sider avvanzat
pożittiv għall-ormonu tar-riċettur u
negattiv għall-HER/2neu, flimkien ma’ exemestane, f’nisa wara
l-menopawża mingħajr mard vixxerali
sintomatiku wara rikorrenza jew progressjoni minħabba inibitur
tal-aromatasi mhux sterojdali.
Tumuri newroendokriniċi ta’ oriġini pankreatika
Afinitor huwa indikat għall-kura ta’ tumuri newroendokriniċi mhux
operabbli jew metastatiċi ta’
oriġini pankreatika b’differenzi sew jew moderati f’adulti
b’marda progr
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Afinitor 2.5 mg pilloli
Afinitor 5 mg pilloli
Afinitor 10 mg pilloli
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Afinitor 2.5 mg pilloli
Kull pillola fiha 2.5 mg everolimus.
_Eċċipjent b’effett magħruf_
Kull pillola fiha 74 mg lactose.
Afinitor 5 mg pilloli
Kull pillola fiha 5 mg everolimus.
_Eċċipjent b’effett magħruf_
Kull pillola fiha 149 mg lactose.
Afinitor 10 mg pilloli
Kull pillola fiha 10 mg everolimus
_Eċċipjent b’effett magħruf_
Kull pillola fiha 297 mg lactose.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola.
Afinitor 2.5 mg pilloli
Pilloli minn bojod sa kemxejn sofor, tawwalin b’qies ta' madwar 10.1
mm fit-tul u 4.1 mm fil-wisa',
b’ġenb tasturat u bl-ebda sinjal dritt, imnaqqxin b’“LCL” fuq
naħa waħda u “NVR” fuq in-naħa
l-oħra.
Afinitor 5 mg pilloli
Pilloli minn bojod sa kemxejn sofor, tawwalin b’qies ta' madwar 12.1
mm fit-tul u 4.9 mm fil-wisa',
b’ġenb tasturat u bl-ebda sinjal dritt, imnaqqxin b’“5” fuq
naħa waħda u “NVR” fuq in-naħa l-oħra.
Afinitor 10 mg pilloli
Pilloli minn bojod sa kemxejn sofor, tawwalin b’qies ta' madwar 15.1
mm fit-tul u 6.0 mm fil-wisa',
b’ġenb tasturat u bl-ebda sinjal dritt, imnaqqxin b’“UHE” fuq
naħa waħda u “NVR” fuq in-naħa
l-oħra.
3
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Kanċer tas-sider avvanzat bl-ormonu tar-riċettur pożittiv
Afinitor hu indikat għall-kura ta’ kanċer tas-sider avvanzat
pożittiv għall-ormonu tar-riċettur u
negattiv għall-HER/2neu, flimkien ma’ exemestane, f’nisa wara
l-menopawża mingħajr mard vixxerali
sintomatiku wara rikorrenza jew progressjoni minħabba inibitur
tal-aromatasi mhux sterojdali.
Tumuri newroendokriniċi ta’ oriġini pankreatika
Afinitor huwa indikat għall-kura ta’ tumuri newroendokriniċi mhux
operabbli jew metastatiċi ta’
oriġini pankreatika b’differenzi sew jew moderati f’adulti
b’marda progr
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 27-06-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 27-06-2022
Public Assessment Report Public Assessment Report Bulgarian 11-12-2018
Patient Information leaflet Patient Information leaflet Spanish 27-06-2022
Public Assessment Report Public Assessment Report Spanish 11-12-2018
Patient Information leaflet Patient Information leaflet Czech 27-06-2022
Public Assessment Report Public Assessment Report Czech 11-12-2018
Patient Information leaflet Patient Information leaflet Danish 27-06-2022
Public Assessment Report Public Assessment Report Danish 11-12-2018
Patient Information leaflet Patient Information leaflet German 27-06-2022
Public Assessment Report Public Assessment Report German 11-12-2018
Patient Information leaflet Patient Information leaflet Estonian 27-06-2022
Public Assessment Report Public Assessment Report Estonian 11-12-2018
Patient Information leaflet Patient Information leaflet Greek 27-06-2022
Public Assessment Report Public Assessment Report Greek 11-12-2018
Patient Information leaflet Patient Information leaflet English 27-06-2022
Public Assessment Report Public Assessment Report English 11-12-2018
Patient Information leaflet Patient Information leaflet French 27-06-2022
Public Assessment Report Public Assessment Report French 11-12-2018
Patient Information leaflet Patient Information leaflet Italian 27-06-2022
Public Assessment Report Public Assessment Report Italian 11-12-2018
Patient Information leaflet Patient Information leaflet Latvian 27-06-2022
Public Assessment Report Public Assessment Report Latvian 11-12-2018
Patient Information leaflet Patient Information leaflet Lithuanian 27-06-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 27-06-2022
Public Assessment Report Public Assessment Report Lithuanian 11-12-2018
Patient Information leaflet Patient Information leaflet Hungarian 27-06-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 27-06-2022
Public Assessment Report Public Assessment Report Hungarian 11-12-2018
Patient Information leaflet Patient Information leaflet Dutch 27-06-2022
Public Assessment Report Public Assessment Report Dutch 11-12-2018
Patient Information leaflet Patient Information leaflet Polish 27-06-2022
Public Assessment Report Public Assessment Report Polish 11-12-2018
Patient Information leaflet Patient Information leaflet Portuguese 27-06-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 27-06-2022
Public Assessment Report Public Assessment Report Portuguese 11-12-2018
Patient Information leaflet Patient Information leaflet Romanian 27-06-2022
Public Assessment Report Public Assessment Report Romanian 11-12-2018
Patient Information leaflet Patient Information leaflet Slovak 27-06-2022
Public Assessment Report Public Assessment Report Slovak 11-12-2018
Patient Information leaflet Patient Information leaflet Slovenian 27-06-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 27-06-2022
Public Assessment Report Public Assessment Report Slovenian 11-12-2018
Patient Information leaflet Patient Information leaflet Finnish 27-06-2022
Public Assessment Report Public Assessment Report Finnish 11-12-2018
Patient Information leaflet Patient Information leaflet Swedish 27-06-2022
Public Assessment Report Public Assessment Report Swedish 11-12-2018
Patient Information leaflet Patient Information leaflet Norwegian 27-06-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 27-06-2022
Patient Information leaflet Patient Information leaflet Icelandic 27-06-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 27-06-2022
Patient Information leaflet Patient Information leaflet Croatian 27-06-2022
Public Assessment Report Public Assessment Report Croatian 11-12-2018

Search alerts related to this product

View documents history